@article{Kumar_2021, title={Network Pharmacology Analysis of Orally Bioavailable SARS-CoV-2 Protease Inhibitor Shows Synergistic Targets to Improve Clinical Efficacy}, volume={7}, url={https://bemsreports.org/index.php/bems/article/view/116}, DOI={10.5530/bems.7.2.8}, abstractNote={<p><strong>Introduction:</strong> Orally bioavailable SARS-CoV-2 antiviral drugs will significantly improve the clinical management of the disease. PF07321332 (PF32) one such orally bioavailable SARSCoV- 2 protease inhibitor which can be helpful to prevent viral replication in the host. <strong>Materials and Methods:</strong> Hence this study evaluated the network pharmacology of PF32 using established methods to predict its potential safety and efficacy. <strong>Results:</strong> PF32 was selective against SARS-CoV-2 proteases without any affinity against SARS-CoV-2 RNA polymerase or its spike protein. While PF32 showed pharmacologically relevant affinity against several targets in human tissues. The target profiling of PF32 indicated a fourfold selectivity towards several proteases in human tissues with an affinity (IC<sub>50</sub>) ranging from 26 to 41 nM. <strong>Conclusion:</strong> The predicted inhibitory effects of PF32 against both host and viral proteases may have synergistic effects for superior clinical efficacy.</p>}, number={2}, journal={Biology, Engineering, Medicine and Science Reports}, author={Kumar, Arun HS}, year={2021}, month={Oct.}, pages={21–24} }